<DOC>
	<DOCNO>NCT00006007</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine LY231514 plus gemcitabine treat woman metastatic breast cancer .</brief_summary>
	<brief_title>LY231514 Plus Gemcitabine Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess antitumor activity pemetrexed disodium combination gemcitabine treatment woman metastatic breast cancer receive anthracycline taxane adjuvant and/or metastatic set 1 chemotherapy regimen metastatic disease ( unless taxane anthracycline ) . - Determine toxicity regimen patient population . - Determine time progression overall survival patient receive regimen . OUTLINE : Patients receive gemcitabine IV 30 minute day 1 8. pemetrexed disodium IV administer 10 minute 90 minute follow gemcitabine day 8 . Treatment continue every 21 day minimum 6 course absence unacceptable toxicity disease progression . Patients achieve complete response receive 2 additional course . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 60 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer clinical evidence metastatic disease Bidimensionally measurable disease If bisphosphonates use , must measurable disease site bone No bone disease Must receive prior anthracycline taxane adjuvant and/or metastatic set No clinically significant pericardial effusion , pleural effusion , ascites unless drain No active CNS metastasis Treated CNS metastasis ben stable least 8 week allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST great 3 time ULN ( 5 time ULN liver metastasis ) Albumin least 3.0 g/dL Renal : Creatinine clearance least 45 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able take folic acid cyanocobalamin ( vitamin B12 ) supplement Body surface area le 3 m^2 No uncontrolled infection No chronic debilitate disease No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy At least 4 week since prior genetic therapy No concurrent immunomodulating agent Chemotherapy : See Disease Characteristics No 3 prior chemotherapy regimen include adjuvant therapy No 1 prior chemotherapy regimen metastatic disease unless taxane anthracycline At least 4 week since prior chemotherapy No prior gemcitabine and/or pemetrexed disodium No concurrent cytostatic cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy great 25 % bone marrow No prior strontium chloride Sr 89 No concurrent radiotherapy Surgery : At least 4 week since prior major surgery Other : No aspirin nonsteroidal antiinflammatory agent 2 day , day , 2 day pemetrexed disodium administration ( 5 day long act agent naproxen , piroxicam , diflunisal , nabumetone )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>